What is mounjaro?
Dual GLP-1 / GIP receptor agonist with strong weight-loss data.
What is mounjaro?
Dual GLP-1 / GIP receptor agonist with strong weight-loss data.
Also known as
- tirzepatide
Quick facts
~22%
average body weight loss at 72 weeks (SURMOUNT-1)
$1,000+
monthly retail price without insurance
60%+
weight regained within 1 year of stopping (without lifestyle change)
Common reasons people choose this procedure
Approaches and motivations vary by surgeon and patient anatomy. Compare techniques and real outcomes on the main Mounjaro page.
Alternatives
Ozempic / Wegovy (semaglutide)
Single GLP-1 receptor agonist. ~15% body weight loss in trials. Lower efficacy than tirzepatide but well-established safety record.
Bariatric surgery
One-time surgical option with comparable or greater long-term efficacy. Higher upfront cost and recovery, but no ongoing medication.
Lifestyle intervention alone
Sustained 5–10% weight loss is realistic for many; significant loss is rare without medication or surgery for obesity-class BMI.